Larotinib/Larotinib production country and background introduction

Larotrectinib was originally developed by Loxo Oncology, an American biopharmaceutical company that focuses on the research and development of targeted cancer treatment drugs, especially in the field of gene-driven cancers. In 2018, the US FDA accelerated its approval of larotrectinib, making it the world's first broad-spectrum anti-cancer targeted drug specifically targeting NTRK gene fusion mutations. In 2019, Loxo Oncology was acquired by global pharmaceutical giant Eli Lilly and Company, further promoting the research and development and market expansion of the drug.

The commercialization of larotrectinib is led by the German pharmaceutical company Bayer (Bayer), which has obtained the global commercialization rights of the drug and is responsible for production and sales. At present, larotrectinib has been approved for marketing in many countries and regions including the United States, Europe, Japan, and China, and has been included in the clinical treatment guidelines of many countries. In China, the National Medical Products Administration (NMPA) approved larotrectinib in 2023 for the treatment of patients with locally advanced or metastatic solid tumors carrying NTRK gene fusions, providing a new treatment option for domestic patients with rare mutation cancers.

From a background perspective, the development of larotrectinib is an important breakthrough in precision cancer medicine. Its birth represents a new direction in gene-driven anti-cancer treatment, breaking through the limitations of traditional treatment methods based on cancer types. Unlike traditional chemotherapy or pan-targeted drugs, larotrectinib accurately identifies NTRK fusion mutations and provides effective treatment without restrictions on cancer types. The global promotion of this drug also shows that with the development of genetic testing technology and the advancement of precision medicine, future cancer treatment will be more inclined to target treatment strategies based on molecular characteristics, rather than classifying treatments based solely on the organ site where the tumor occurs.

Reference materials:https://www.vitrakvi.com/